Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Immunotherapy has generated a lot of excitement in oncology. As such, there is a lot of interest in investigating combinations with immunotherapy. There is also evidence indicating that TKIs could enhance the immune microenvironment, leading to enhanced responses. Combinations of the like with regorafenib and TAS-102 may have the same effect, says Lockhart.

In addition, the optimal sequence of these agents is under evaluation. For example, in the ongoing phase II REVERCE trial, patients with KRAS exon 2 wild-type mCRC will be randomized to receive sequential therapy with regorafenib followed by cetuximab (Erbitux) or the reverse sequence following standard chemotherapy, says Lockhart. Such studies will have to be supplemented with biomarker analysis before the paradigm changes, he concludes.